Mycobacteriophages in diagnosis and alternative treatment of mycobacterial infections

Frontiers in Microbiology

Microbiology

Zhaoli Li¹  Jinmiao Song²  Ningning Song²  Xiaotian Li²  Hui Wang²  Ren Fang²  Shuxian Wang²  Xudong Ouyang² 

[1] SAFE Pharmaceutical Technology Co. Ltd., Beijing, China;School of Life Science and Technology, Weifang Medical University, Weifang, China;Weifang Key Laboratory of Respiratory Tract Pathogens and Drug Therapy, Weifang, China;

关键词: mycobacteriophage;    mycobacterial infection;    non-tuberculous mycobacteria;    phage therapy;    Mycobacterium tuberculosis;   

DOI  :  10.3389/fmicb.2023.1277178

 received in 2023-08-16, accepted in 2023-09-12,  发布年份 2023

来源: Frontiers

【 摘 要 】

Antimicrobial resistance is an increasing threat to human populations. The emergence of multidrug-resistant “superbugs” in mycobacterial infections has further complicated the processes of curing patients, thereby resulting in high morbidity and mortality. Early diagnosis and alternative treatment are important for improving the success and cure rates associated with mycobacterial infections and the use of mycobacteriophages is a potentially good option. Since each bacteriophage has its own host range, mycobacteriophages have the capacity to detect specific mycobacterial isolates. The bacteriolysis properties of mycobacteriophages make them more attractive when it comes to treating infectious diseases. In fact, they have been clinically applied in Eastern Europe for several decades. Therefore, mycobacteriophages can also treat mycobacteria infections. This review explores the potential clinical applications of mycobacteriophages, including phage-based diagnosis and phage therapy in mycobacterial infections. Furthermore, this review summarizes the current difficulties in phage therapy, providing insights into new treatment strategies against drug-resistant mycobacteria.

【 授权许可】

Unknown   
Copyright © 2023 Ouyang, Li, Song, Wang, Wang, Fang, Li and Song.